Latest Conference Articles

Dr Allaf on Perioperative Nivolumab Vs Observation Following Nephrectomy in RCC

Mohamad Ezzeddine Allaf, MD, discusses the results of perioperative nivolumab vs observation in patients with renal cell carcinoma who undergo nephrectomy.

Trastuzumab Deruxtecan Maintains Clinical Benefit in Metastatic Gastric/GEJ Cancer

Trastuzumab deruxtecan continued to demonstrate a clinical benefit and tolerable safety profile for patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a trastuzumab-based regimen.

Amcenestrant Provides Numerically Similar PFS to Endocrine Therapy in Endocrine-Resistant ER+ Advanced Breast Cancer

Amcenestrant did not significantly improve progression-free survival over physician’s choice of endocrine monotherapy in patients with endocrine-resistant, estrogen receptor–positive, HER2-negative advanced breast cancer, but it did provide a benefit that was numerically comparable, according to data from the phase 2 AMEERA-3 trial.

Second-line Cemiplimab Produces Long-Term OS Benefit in Recurrent/Metastatic Cervical Cancer

Cemiplimab maintained an overall survival benefit vs chemotherapy as a second-line treatment for patients with recurrent or metastatic cervical cancer who received prior platinum-based chemotherapy.

Sacituzumab Govitecan-hziy Demonstrates Promising Efficacy in HER2-low/HER2-0 Metastatic Breast Cancer

Sacituzumab govitecan improved progression-free survival and overall response rate among patients with HER2-low or HER2 immunohistochemistry zero, hormone receptor­–positive metastatic breast cancer.

ADP-A2M4CD8 Shows Promising Activity Across MAGE-A4+ Unresectable or Metastatic Tumor Types

An updated analysis of the phase 1 SURPASS trial showed that ADP-A2M4CD8, a next-generational autologous T-cell receptor designed to patients with solid tumors, may be an effective therapy in MAGE-A4-positive disease.

Lasofoxifene Improves Responses Vs Fulvestrant in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer

Single-agent lasofoxifene did not produce a statistically significant improvement in progression-free survival vs fulvestrant for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.

Neoadjuvant T-VEC Plus Surgery Demonstrates Long-Term Efficacy in Resectable Melanoma

Neoadjuvant talimogene laherparepvec plus surgery provided sustained, durable improvements in efficacy vs surgery alone in patients with resectable stage IIIB to IVM1a melanoma.

Abemaciclib Plus Trastuzumab Results in Numerical OS Improvement Vs SOC in HR+, HER2+ Advanced Breast Cancer

The addition of abemaciclib to trastuzumab, with or without fulvestrant, provided a numerical overall survival improvement over standard-of-care trastuzumab plus chemotherapy in patients with hormone receptor–positive, HER2-positive advanced breast cancer, according to data from the monarcHER trial.

Exposure to Environmental Carcinogens May Increase Risk for EGFR+ NSCLC

Increased exposure to particulate matter may be a mechanistic driver for EGFR-positive non–small cell lung cancer, prompting a focus on limiting exposure to air pollutants and an increased need for molecular testing.

LEAP-002 Trial Misses Primary End Points, But Data Support Role of Lenvatinib Monotherapy as SOC in Frontline HCC

Although the primary end points of the phase 3 LEAP-002 trial did not meet prespecified statistical significance with regard to survival benefit achieved with lenvatinib plus pembrolizumab, the median overall survival observed with lenvatinib monotherapy supports its role as a standard of care in frontline advanced hepatocellular carcinoma treatment.

TILs Demonstrate Improved PFS Vs Ipilimumab in Unresectable Melanoma

A tumor-infiltrating lymphocyte therapy manufactured at various centers in the Netherlands Cancer Institute elicited a 50% reduction in the risk of progression or death vs ipilimumab in patients with stage IIIC/IV unresectable, treatment-refractory melanoma.

Camrelizumab/Rivoceranib Combo Significantly Improves Survival Over Sorafenib in Unresectable HCC

First-line treatment with camrelizumab plus rivoceranib resulted in a significant improvement in progression-free survival and overall survival compared with sorafenib in patients with unresectable hepatocellular carcinoma.

Nirogacestat Improves PFS in Progressing Desmoid Tumors

Nirogacestat led to a 71% reduction in the risk of disease progression or death compared with placebo in patients with progressive desmoid tumors.

Advances in Breast and Gastrointestinal Cancers at ESMO 2022: Drs Rugo and Abou-Alfa

First-line Dalpiciclib Significantly Improves PFS Outcomes for Patients With HR+/HER2– Advanced Breast Cancer

The combination of the CDK4/6 inhibitor dalpiciclib plus letrozole or anastrozole reduced the risk of disease progression by 49% vs chemotherapy alone in patients with treatment-naïve, hormone receptor–positive, HER2-negative advanced breast cancer.

CLDN6 CAR T-Cell Therapy Shows Encouraging Efficacy in Relapsed/Refractory Advanced Solid Tumors

The investigational carcinoembryonic antigen claudin 6 (CLDN6)–directed CAR T-cell therapy BNT211-01 displayed clinical activity both as monotherapy and in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.

Oleclumab/Durvalumab Plus Chemotherapy Combo Fails to Reach Clinical Benefit End Point in Advanced TNBC

Adding oleclumab to durvalumab and chemotherapy did not increase the clinical benefit rate vs durvalumab plus chemotherapy alone as a first-line treatment for patients with advanced triple-negative breast cancer.

Sacituzumab Govitecan Produces Significant Efficacy Benefits in Pretreated HR+/HER2- Metastatic Breast Cancer

Sacituzumab govitecan generated statistically significant and clinically meaningful benefits in overall survival and responses vs physician’s choice of treatment in pretreated patients with hormone receptor–positive, HER2-negative metastatic breast cancer who were resistant to endocrine therapy.

Abemaciclib Plus Aromatase Inhibitor Generates Survival Benefit in HR+/HER2- Breast Cancer

The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer.

Preoperative Nivolumab Alone or With Relatlimab Allows for Surgical Feasibility in Resectable NSCLC

Preoperative nivolumab with or without relatlimab increased surgical feasibility in patients with resectable non–small cell lung cancer.

Higher-Dose Rhenium-186 Nanoliposome Demonstrates OS Advantage in Recurrent Glioma

Rhenium-186 nanoliposome administered at doses exceeding 100 Gy demonstrated promising safety and efficacy results in patients with recurrent glioma.

Olaparib Maintenance Provides Sustained OS Benefit in Newly Diagnosed, BRCA-Mutated, Advanced Ovarian Cancer

Two years of olaparib maintenance therapy elicited a long-term overall survival benefit vs placebo in patients with newly diagnosed advanced ovarian cancer harboring a BRCA mutation.

Olaparib Plus Bevacizumab Maintenance Therapy Provides OS Benefit in Advanced HRD-Positive Ovarian Cancer

Maintenance olaparib plus bevacizumab following first-line standard-of-care treatment improved overall survival in patients with newly diagnosed advanced ovarian cancer, particularly those with homologous recombination deficiency.

Rucaparib Demonstrates Survival Benefits in BRCA1/2-Mutated, Relapsed Ovarian Cancer.

Rucaparib elicited a progression-free survival benefit and comparable overall survival (OS) vs chemotherapy in patients with BRCA1/2-mutated, relapsed ovarian cancer who were sensitive to platinum-based chemotherapy.

Second-line Ramucirumab Showcases Survival Benefits in HCC, Irrespective of Extrahepatic Spread

Second-line treatment with ramucirumab produced an overall survival benefit vs placebo in Chinese patients with hepatocellular carcinoma, irrespective of the presence of extrahepatic spread, according to findings from an exploratory analysis of the phase 3 REACH and REACH-2 trials.

Black Patients With HCC, Those Living in High-Poverty Neighborhoods Have Higher Odds of Experiencing Treatment Delays

Data from a recent analysis revealed that nearly 1 in 7 patients with hepatocellular carcinoma experience treatment delays, with higher odds observed in Black patients and those living in high poverty neighborhoods.

Sequential Combo of Regorafenib and Nivolumab Shows Manageable Safety in Sorafenib-Pretreated HCC

The sequential treatment of regorafenib followed by nivolumab was found to have an acceptable toxicity profile in patients with hepatocellular carcinoma who progressed on and tolerated first-line sorafenib, according to early data from the phase 1/2a GOING trial.

Investigators Set Sights on Optimizing CAR T-Cell Therapy in Lymphoma

Five years since the first FDA approval of CAR T-cell therapy in relapsed/refractory lymphoma, there is still much to learn about how to optimize its use, according to Sattva S. Neelapu, MD.

Cilta-cel Induces Favorable MRD Negativity Rates in Heavily Pretreated Myeloma After Prior BCMA-Directed Therapy

Ciltacabtagene autoleucel elicited high rates of minimal residual disease negativity in patients with heavily pretreated multiple myeloma who received prior treatment with a BCMA-targeted therapy.